Howard and colleagues report1 a randomized clinical trial in which 554 patients clinically diagnosed with early Alzheimer disease were randomized to 200 mg/d or 400 mg/d of the broad-spectrum antibiotic minocycline or to placebo and followed up for 24 months. Clinical outcomes were a structured Mini-Mental State Examination (MMSE)2 and the Bristol Activities of Daily Living scale. About 62% of the 200 mg/d minocycline–treated group compared with 64% of the placebo-treated group completed 2 years of treatment; only 29% of the group receiving 400 mg/d of minocycline completed the trial. There was no evidence for efficacy of minocycline at either dose. Planned subset and sensitivity analyses to assess predictors of outcomes and potential sources of bias (eg, dropout bias) did not suggest that outcomes could have been different.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Schneider LS. Pragmatic Trials and Repurposed Drugs for Alzheimer Disease. JAMA Neurol. 2020;77(2):162–163. doi:10.1001/jamaneurol.2019.3784
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: